WO2008069349A1 - Potentiation of cellular immunity using histone deacetylase (hdac) inhibitors - Google Patents
Potentiation of cellular immunity using histone deacetylase (hdac) inhibitors Download PDFInfo
- Publication number
- WO2008069349A1 WO2008069349A1 PCT/JP2007/074067 JP2007074067W WO2008069349A1 WO 2008069349 A1 WO2008069349 A1 WO 2008069349A1 JP 2007074067 W JP2007074067 W JP 2007074067W WO 2008069349 A1 WO2008069349 A1 WO 2008069349A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- cellular immunity
- hdac
- enhancer
- substance
- Prior art date
Links
- 108090000353 Histone deacetylase Proteins 0.000 title claims abstract description 64
- 102000003964 Histone deacetylase Human genes 0.000 title claims abstract description 64
- 230000007969 cellular immunity Effects 0.000 title claims abstract description 53
- 239000003112 inhibitor Substances 0.000 title description 5
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 75
- 201000011510 cancer Diseases 0.000 claims abstract description 64
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 39
- 239000000126 substance Substances 0.000 claims abstract description 39
- 238000011282 treatment Methods 0.000 claims abstract description 30
- 239000003623 enhancer Substances 0.000 claims abstract description 25
- 208000015181 infectious disease Diseases 0.000 claims abstract description 21
- 244000000010 microbial pathogen Species 0.000 claims abstract description 18
- 230000014509 gene expression Effects 0.000 claims description 68
- 238000000034 method Methods 0.000 claims description 62
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 49
- 241000700605 Viruses Species 0.000 claims description 46
- 229960000604 valproic acid Drugs 0.000 claims description 46
- 201000010099 disease Diseases 0.000 claims description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 33
- 210000001519 tissue Anatomy 0.000 claims description 29
- 230000002708 enhancing effect Effects 0.000 claims description 28
- 206010006187 Breast cancer Diseases 0.000 claims description 25
- 208000026310 Breast neoplasm Diseases 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 21
- 230000002265 prevention Effects 0.000 claims description 17
- 239000004480 active ingredient Substances 0.000 claims description 12
- 206010060862 Prostate cancer Diseases 0.000 claims description 11
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 11
- 238000012216 screening Methods 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 10
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 7
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 7
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 7
- 230000001524 infective effect Effects 0.000 claims description 7
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 7
- 108020004999 messenger RNA Proteins 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 241000713666 Lentivirus Species 0.000 claims description 5
- 241001529453 unidentified herpesvirus Species 0.000 claims description 5
- 238000002487 chromatin immunoprecipitation Methods 0.000 claims description 4
- 238000012408 PCR amplification Methods 0.000 claims description 3
- 238000009169 immunotherapy Methods 0.000 abstract description 4
- 208000005623 Carcinogenesis Diseases 0.000 abstract description 3
- 230000036952 cancer formation Effects 0.000 abstract description 3
- 231100000504 carcinogenesis Toxicity 0.000 abstract description 3
- 238000009117 preventive therapy Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 100
- 102100027314 Beta-2-microglobulin Human genes 0.000 description 44
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 43
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 31
- 230000001965 increasing effect Effects 0.000 description 25
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 24
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 21
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 20
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 20
- 230000003247 decreasing effect Effects 0.000 description 19
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 17
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 16
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 16
- 102000043129 MHC class I family Human genes 0.000 description 11
- 108091054437 MHC class I family Proteins 0.000 description 11
- 230000001413 cellular effect Effects 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 101150076800 B2M gene Proteins 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 10
- 208000037581 Persistent Infection Diseases 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 108010077544 Chromatin Proteins 0.000 description 8
- 108010033040 Histones Proteins 0.000 description 8
- 210000003483 chromatin Anatomy 0.000 description 8
- 239000000654 additive Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 230000009385 viral infection Effects 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000006947 Histones Human genes 0.000 description 4
- -1 PXDlOl Chemical compound 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000008399 tap water Substances 0.000 description 4
- 235000020679 tap water Nutrition 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102100039869 Histone H2B type F-S Human genes 0.000 description 3
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 241000712079 Measles morbillivirus Species 0.000 description 3
- 241000711386 Mumps virus Species 0.000 description 3
- 241001631646 Papillomaviridae Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000006196 deacetylation Effects 0.000 description 3
- 238000003381 deacetylation reaction Methods 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000272525 Anas platyrhynchos Species 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 2
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 2
- 108010075704 HLA-A Antigens Proteins 0.000 description 2
- 108010052199 HLA-C Antigens Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- 239000012083 RIPA buffer Substances 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 201000006449 West Nile encephalitis Diseases 0.000 description 2
- 206010057293 West Nile viral infection Diseases 0.000 description 2
- 238000011394 anticancer treatment Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 230000006718 epigenetic regulation Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000006195 histone acetylation Effects 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- VAZAPHZUAVEOMC-UHFFFAOYSA-N tacedinaline Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000007923 virulence factor Effects 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- 229960000237 vorinostat Drugs 0.000 description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- JWOGUUIOCYMBPV-GMFLJSBRSA-N (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone Chemical compound N1C(=O)[C@H](CCCCCC(=O)CC)NC(=O)[C@H]2CCCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-GMFLJSBRSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
- MAUCONCHVWBMHK-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)-oxomethyl]phenoxy]ethyl]-2-benzofurancarboxamide Chemical compound O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MAUCONCHVWBMHK-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 208000003829 American Hemorrhagic Fever Diseases 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 201000009695 Argentine hemorrhagic fever Diseases 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 208000034200 Bolivian hemorrhagic fever Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 208000006339 Caliciviridae Infections Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 206010008761 Choriomeningitis lymphocytic Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- JOJYUFGTMHSFEE-YONYXQDTSA-M Cytarabine ocfosphate Chemical compound [Na+].O[C@H]1[C@H](O)[C@@H](COP([O-])(=O)OCCCCCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 JOJYUFGTMHSFEE-YONYXQDTSA-M 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- DLVJMFOLJOOWFS-UHFFFAOYSA-N Depudecin Natural products CC(O)C1OC1C=CC1C(C(O)C=C)O1 DLVJMFOLJOOWFS-UHFFFAOYSA-N 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 208000030820 Ebola disease Diseases 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000714201 Feline calicivirus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 241000150562 Hantaan orthohantavirus Species 0.000 description 1
- 206010019143 Hantavirus pulmonary infection Diseases 0.000 description 1
- 208000032982 Hemorrhagic Fever with Renal Syndrome Diseases 0.000 description 1
- 208000000464 Henipavirus Infections Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000701041 Human betaherpesvirus 7 Species 0.000 description 1
- 241000342334 Human metapneumovirus Species 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 108700005089 MHC Class I Genes Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000000932 Marburg Virus Disease Diseases 0.000 description 1
- 208000030156 Marburg disease Diseases 0.000 description 1
- 201000011013 Marburg hemorrhagic fever Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241001643857 Menangle virus Species 0.000 description 1
- 206010066226 Metapneumovirus infection Diseases 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 208000010359 Newcastle Disease Diseases 0.000 description 1
- 206010064034 Nipah virus infection Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- JWOGUUIOCYMBPV-UHFFFAOYSA-N OT-Key 11219 Natural products N1C(=O)C(CCCCCC(=O)CC)NC(=O)C2CCCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-UHFFFAOYSA-N 0.000 description 1
- 241000713112 Orthobunyavirus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000007634 Peste-des-Petits-Ruminants Diseases 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 229940022005 RNA vaccine Drugs 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000008104 Reoviridae Infections Diseases 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 208000005074 Retroviridae Infections Diseases 0.000 description 1
- 241000606651 Rickettsiales Species 0.000 description 1
- 208000006257 Rinderpest Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 241000369757 Sapovirus Species 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 229930189037 Trapoxin Natural products 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 208000007885 Vesicular Exanthema of Swine Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 238000000787 affinity precipitation Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 108010082820 apicidin Proteins 0.000 description 1
- 229930186608 apicidin Natural products 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000008921 border disease Diseases 0.000 description 1
- 208000000982 bovine virus diarrhea-mucosal disease Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- GYKLFBYWXZYSOW-UHFFFAOYSA-N butanoyloxymethyl 2,2-dimethylpropanoate Chemical compound CCCC(=O)OCOC(=O)C(C)(C)C GYKLFBYWXZYSOW-UHFFFAOYSA-N 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 208000014058 canine distemper Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- DLVJMFOLJOOWFS-INMLLLKOSA-N depudecin Chemical compound C[C@@H](O)[C@@H]1O[C@H]1\C=C\[C@H]1[C@H]([C@H](O)C=C)O1 DLVJMFOLJOOWFS-INMLLLKOSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 230000009066 down-regulation mechanism Effects 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229960001483 eosin Drugs 0.000 description 1
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 201000005648 hantavirus pulmonary syndrome Diseases 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 201000010284 hepatitis E Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000002621 immunoprecipitating effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 208000001419 lymphocytic choriomeningitis Diseases 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 108700021021 mRNA Vaccine Proteins 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 108010001062 polysaccharide-K Proteins 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 238000000015 thermotherapy Methods 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 108010060597 trapoxin A Proteins 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 208000005925 vesicular stomatitis Diseases 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a method for enhancing cellular immunocompetence by increasing the level of expression of major histocompatibility complex (MHC) class I antigen on a cell surface by using histone deacetylase (HDAC) inhibitors.
- MHC major histocompatibility complex
- HDAC histone deacetylase
- the present invention relates to a method for enhancing cellular immunity using HDAC inhibitors.
- the present invention relates to an application of such methods for enhancing cellular immunity to a prevention of carcinogenesis or cancer recurrence, an immunotherapy of an existing cancer, or a treatment of infection by pathogenic microorganism.
- Biological immunity is generally classified into humoral immunity depending on antibody production and cellular immunity depending on targeted cellular injury by lymphocytes.
- the most important immunity in resisting against pathogenic microorganism infected in cells or a cellular disease such as a cancer is cellular immunity. Therefore, enhancing such cellular immunocompetence is expected to exert efficacy in wide areas such as a prevention or treatment of cancer and a treatment of infection by pathogenic microorganism such as virus and bacteria.
- HLA human leukocyte antigen
- antigen peptides as degradation products from cancer antigen proteins in cancer cells or antigen peptides as degradation products from virulence factor-derived proteins in cells infected with virus and the like, each bind to the HLA class I molecule and appear on a cell surface.
- T cells recognize the antigen peptide/HLA complex on a target cell surface by the T-cell antigen receptor on the cell surface and discriminate between normal cells and cancer/infected cells. This means that, when the expression of the HLA class I molecule is suppressed, the target cell-recognizing mechanism by the T cell would not function normally.
- the MHC class I antigen is composed of a hetero-dimer of two molecules, that is a heavy chain encoding mainly three kinds of genes: HLA-A, HLA- B and HLA-C, and a light chain encoding one gene called j3 2-microglobulin(B2M) .
- B2M When B2M is not normally expressed, the formation of a mature HLA complex and the transportation to the cell membrane surface are impaired, resulting in lowered expression of the products of all the HLA-A, HLA-B, and HLA-C genetic loci.
- MHC class I antigen is expressed on the cellular surface of almost all somatic cells excluding testicular cells.
- cancer cells such as breast and prostatic cancer cells
- the expression of cell surface MHC class I antigen is frequently decreased.
- a downregulation mechanism due to the gene mutation in the heavy or light chain is known (Non-patent document 1), but its details are unknown.
- inhibition of the expression of class I antigen has also been known, and its various mechanisms have been reported.
- each virus has plural intricate strategies to inhibit the class I expression.
- cytomegalovirus expresses four genes (US3, US2, USIl and US6) which interfere with the MHC class I pathway: US3 inhibits the export of the MHC class I complexes from the endoplasmic reticulum, US2 and USIl induce the rapid destruction of the MHC class I complexes by the proteasome, and US 6 inhibits the peptide supply into the endoplasmic reticulum, all interfering with the function of MHC class I (Non-patent document 2). HIV virus not only inhibits the transcription of B2M and class I genes through Tat (Non-patent document 3) but also interferes with the MHC class I function by altering the transport pathway for the class I product through Nef (Non-patent document 4).
- HDAC histone deacetylase
- HDAC inhibitors for HDAC belonging to each class are not necessarily strict, but for example, it has been reported that tricostatin A (TSA) inhibits class I and II HDAC while valproic acid (VPA) is preferably inhibits class I HDAC compared with class ⁇ HDAC, and the like (Non-patent documents 5 and 6).
- TSA tricostatin A
- VPA valproic acid
- Non Patent Citation 1 Seliger, B., et al., Semin Cancer Biol 2002, 12: 3-13.
- Non Patent Citation 2 Mirandola, P., et al., J Infect Dis. 2006 Apr 1; 193(7): 917-26.
- Non Patent Citation 3 Carroll, IR., et al., MoI Immunol. 1998 Dec; 35(18): 1171-8.
- Non Patent Citation 4 Lubben, NB., et al., MoI Biol Cell. 2007.
- Non Patent Citation 5 Kim, DH., et al., J Biochem MoI Biol. 2003. Jan 31; 36(1):
- Non Patent Citation 6 Gottlich, M., et al., EMBO J. 2001. Dec 17; 20(24) -.6969-78.
- the present inventors found that, in many cancer cells, the expression level of MHC class I to the cellular surface is decreased despite the absence of their mutational change in both MHC class I heavy chain and light chain genes. They further found that, in certain cancer cells, the cause of the suppression of the expression of MHC class I antigen is ascribable to deacetylation of histone bound to the B2M gene. Then, it was demonstrated that HDAC inhibitors, when added to the cells whose expression of B2M was decreased, increased the expression level of MHC class I on a cellular surface as well as the level of B2M protein.
- the enhancer of cellular immunity according to the present invention is characterized in that a substance having an inhibitory activity of histone deacetylase (HDAC) is comprised as an active ingredient.
- HDAC histone deacetylase
- a substance having an inhibitory activity of HDAC is preferably valproic acid.
- the enhancer of cellular immunity according to the present invention is preferably used for treatment or prevention of a disease in which ⁇ 2-microglobulin(B2M) expression is suppressed at the disease site.
- the enhancer of cellular immunity is preferably used for treatment or prevention a disease in a subject suffering from, or at risk of, an infection caused by a cell-invading pathogenic microorganism/factor; or in a subject suffering from, or at risk of, a disease.
- the pathogenic microorganism is preferably a cell-invading bacteria.
- the factor is preferably a virus.
- the virus is more preferably one or plurality of viruses selected from the group consisting of members of the herpesvirus, papovavirus, lentivirus, and paramyxovirus families.
- the disease is preferably a cancer, more preferably prostate cancer or oral cancer, and furthermore preferably breast cancer.
- the enhancer of HLA class I expression according to the present invention is characterized by conprising a substance having an inhibitory activity of HDAC as an active ingredient.
- the substance having an inhibitory activity of HDAC is preferably valproic acid.
- the enhancer of B2M expression according to the present invention is characterized by conprising a substance having an inhibitory activity of HDAC as an active ingredient.
- the substance having an inhibitory activity of HDAC is preferably valproic acid.
- the method for enhancing cellular immunity according to the present invention is characterized by comprising a step dosing a subject a composition containing a substance having an inhibitory activity of HDAC as an active ingredient.
- the substance having an inhibitory activity of HDAC is preferably valproic acid.
- the method for enhancing cellular immunity according to the present invention is preferably used for treatment or prevention of a disease in which j3 2-microglobulin(B2M) expression is suppressed at the disease site.
- the subject is preferably infected with a pathogenic microorganism, and the pathogenic microorganism is more preferably a virus, and the virus is furthermore preferably one or plurality of viruses selected from the group consisting of members of the herpesvirus, papovavirus, lentivirus, and paramyxovirus families.
- the disease is preferably a cancer, and the cancer is more preferably prostate cancer or oral cancer, and the cancer is furthermore preferably breast cancer.
- the method for enhancing cellular immunity according to the present invention can be used for prevention or treatment of a disease in a subject suffering from, or at risk of, an infection caused by a cell-invading pathogenic microorganism/ factor comprising any virus; or in a subject suffering from, or at risk of, cancer such as breast cancer, prostate cancer, oral cancer, or the like.
- the method for screening subjects whose cellular immunity is to be enhanced by using a substance having an inhibitory activity of HDAC according to the present invention is characterized by comprising a step obtaining an infective tissue or cancer . tissue from the subjects, a step extracting B2M or mRNA encoding B2M from said tissue, and a step comparing the amount of said B2M or said mRNA encoding B2M with an amount of a control.
- the method for screening subjects whose cellular immunity is to be enhanced by using a substance having an inhibitory activity of HDAC according to the present invention is characterized by comprising a step obtaining an infective tissue or cancer tissue from the subject, a step performing chromatin immunoprecipitation with said tissue to obtain a precipitate, and performing PCR amplification of DNA fragments of B2M from said precipitate to obtain amplified DNA fragments, and a step determining whether said amplified DNA fragments exist.
- the substance having an inhibitory activity of HDAC is preferably valproic acid.
- an expression level of MHC class I antigen can be increased in target cells.
- the injurious effect on the target cell by the cytotoxic T cell is enhanced in a host. Therefore, by using the method of the invention, direct treatment can be performed or the therapeutic effect of a concurrent therapy can be increased in a disease such as a microbial infection, a cancer and the like.
- target cells whose expression is decreased through the decreased protein level of HLA class I light chain can be selected, and hence a subject suffering from, or at risk of occurrence/recurrence of, a disease in which B2M ex- pression is suppressed at the diseased site can be screened.
- treatment of a disease such as a microbial infection, a cancer and the like, can be performed and the therapeutic effect of a concurrent therapy can be increased.
- Fig.l is a drawing showing that intracellular B2M gene-binding histone proteins are deacetylated by chromatin sedimentation.
- the left panel is an example in which MCF-7 human breast cancer cells were cultured in the presence of TSA, and the right panel is an example in which HMC-I human breast cancer cell line was cultured in the presence of VPA. Since in both cases, B2M gene was almost undetected in anti- acetylated histone antibody immunoprecipitates in untreated state, it is found that histone proteins were deacetylated in B2M gene region. B2M genes have been detected in the same immunoprecipitates by acting TSA or VPA.
- FIG.2 is a drawing showing that the level of intracellular B2M protein is increased by HDAC inhibitor.
- the left panel is an example in which HMC-I human breast cancer cells were cultured and the right panel is an example in which MCF-7 human breast cancer cell line was caltured, for 24 hours in the presence of TSA, respectively.
- TSA HDAC inhibitor
- FIG.3 is a drawing showing that the level of MHC class I antigen on a cell surface was increased by an HDAC inhibitor TSA.
- the left panel is the example in which HMC-I human breast cancer cells were cultured and the right panel is an example in which MCF-7 human breast cancer cell line was cultured, for 24 hours in the presence of TSA, respectively.
- MHC class I antigen on a cell surface which was in extremely lower level in non-treated state was increased by about ten times by the action of an HDAC inhibitor TSA.
- the longitudinal axis indicates cell count, and the horizontal axis indicates fluorescence intensity.
- FIG.4 is a drawing showing that the level of MHC class I antigen on a cell surface was increased by an HDAC inhibitor VPA, the safety of which has been established in human.
- HMC-I human breast cancer cells were cultured for 48 hours in the presence of 4 mM VPA. It is shown that MHC class I antigen on a cell surface which is in lower level in non-treated state is increased by about ten times by the action of an HDAC inhibitor VPA.
- the longitudinal axis indicates cell count, and the horizontal axis indicates fluorescence intensity.
- FIG.5 is a drawing showing a cancer case in which the expression of HLA class I antigen (heavy chain and light chain B2M protein) on a cell surface is positive (upper two panels, Case A), a cancer case of negative (lower two panels, Case B).
- the left upper and lower two panels are the drawing in which the breast cancer samples were immunostained with anti-HLA class I heavy chain antibody (EMR8-5 antibody), and the right upper and lower two panels are the drawing in which the same breast cancer samples were immunostained with anti-B2M antibody (EMRB6 antibody).
- the drawings show that there are HLA class I positive cancer (Case A) and negative cancer (Case B) in human breast cancer tissues.
- FIG.6 Immunostaining was performed with similar anti-HLA class I heavy chain antibody (EMR8-5 antibody) to that in Fig.5, and cell surface expression of HLA class I antigen was searched on various types of human cancer tissues. As shown in the table, it is indicated that the frequencies of the expressions are different depending on the types of cancer, but there exist the cancer in which HLA class I antigen is positive and the cancer of negative or of decreased expression with regard to all the cancer types. It is noticed that the frequency in which the expression of HLA class I antigen is decreased is higher especially in breast cancer and prostate cancer.
- FIG.7 Fig.7 is a drawing showing that the expression level of HLA class I antigen is increased in tumor of VPA-administrated mouse (VPA (+)) compared to control group
- FIG.8 is a drawing showing that the expression level of B2M is increased in tumor of VPA-administrated mouse (VPA (+)) compared to control group (VPA (-)).
- FIG.9 is a drawing showing that the expression level of HLA class I antigen is increased in human immunodeficiency virus (HIV) persistent infection T cells in the presence of VPA (VPA (+)) compared to control group (VPA (-)).
- FIG.lO Fig.lO is a drawing showing that the expression level of HLA class I antigen is increased in papilloma virus persistent infection epithelial cell line (HeLa cells) in the presence of VPA (VPA (+)) compared to control group (VPA (-)).
- FIG.11 is a drawing showing that the expression level of HLA class I antigen is increased in EB virus persistent infection Fig.11 B cells (LG2EBV cells) in the presence of VPA (VPA (+)) compared to control group (VPA (-)).
- FIG.l2 is a drawing showing that the expression level of HLA class I antigen is increased in mumps virus persistent infection B cells (Akata-MPl cells) in the presence of VPA (VPA (+)) compared to control group (VPA (-)).
- FIG.l3 is a drawing showing that the expression level of HLA class I antigen is increased in measles virus persistent infection B cells (Raji-ZH cells) in the presence of VPA (VPA (+)) compared to control group (VPA (-)). Best Mode for Carrying Out the Invention Hereafter, preferred embodiments of the present invention are explained.
- the first embodiment of the present invention relates to a composition containing a substance having an inhibitory activity of HDAC as an active component.
- a substance having an inhibitory activity of HDAC may be anything as long as it is the HDAC inhibitor capable of being administered to human or animals.
- one of the agents having HDAC inhibitory action, the safety of which is most established in human at this time is valproic acid (VPA).
- VPA valproic acid
- the dosage can be adjusted accordingly depending on body weight and age, pharmacokinetics, safety, effect, purpose, administration method and the like.
- any HDAC inhibitor besides VPA can be used equivalently.
- the agents such as phenylbutyric acid, FK228 (Depsipeptide), SAHA (suberoylanilide hydroxamic acid), PXDlOl, CI-994 (N-acetyl dinaline), MGCD0103, Pivanex, CRA-024781, MS-275, LBH589, MG989, LAQ-824, and NVP-LAQ824 are already under clinical trials in another use separating from the present invention.
- HDAC inhibitors such as TSA, Trapoxin, CHAP, Apicidin and Depudecin are known. Therefore, as "a substance having an inhibitory activity of HDAC” it is possible to use an HDAC inhibitor having equivalent action and/or specificity to VPA in the effect of the present invention.
- HDAC inhibitor can be referred to as an inhibitor to the HDAC of class I and/or class ⁇ .
- a composition containing the substance having an inhibitory activity of HDAC in the present invention as an active ingredient is used for treatment or prevention of the diseases in which B2M expression is suppressed at the diseased site.
- the aforementioned diseased site means, for example if it is cancer, cancer cells; if it is infection, the cells infected by pathogenic microorganism.
- a subject to be administrated with the composition containing the substance having an inhibitory activity of HDAC in the present invention as an active ingredient is not limited particularly, the subject includes a cancer patient, a subject at a risk of onset or recurrence of cancer, or a subject infected with pathogenic microorganism such as virus and the others, or a subject at a risk of the infection.
- Infection with pathogenic microorganism in the present invention is not particularly limited, and it includes, for example, the infections by viruses containing viruses of the herpesvirus family including EB virus, cytomegalovirus, HSV, HHV-7 and the like, viruses of the papovavirus family including papillomavirus and the like, viruses of the parvovirus family, viruses of the adenovirus family, viruses of the hepadnavirus family including HBV and the like, viruses of the poxvirus family, viruses of the picornavirus family including coxsackievirus belonging to enterovirus, HAV and the like, viruses of the coronavirus family including SARS virus, viruses of the togavirus family, viruses of the flavivirus family including HCV, West Nile fever virus and the like, viruses of the rhabdovirus family, viruses of the filovirus family, viruses of the paramyxovirus family including measles virus, epidemic parotitis virus (mumps virus), parainfluenza virus and the like, viruses
- the aforementioned infections are not particularly limited, but it is possible to apply to the subject having or at a risk of, for example, reovirus infection, SARS, retrovirus infection, yellow fever, Japanese encephalitis, dengue fever, West Nile fever, bovine viral diarrhea-mucosal disease, hog cholera, border disease, hepatitis C, foot-and-mouth disease, poliomyelitis (acute poliomyelitis), hepatitis A, cold, rubella, Sindbis virus infection, equine viral arteritis, simian hemorrhagic fever, norovirus infection, sapovirus infection, rabbit hemorrhagic disease, feline calicivirus disease, vesicular exanthema of swine, hepatitis E, Marburg disease, Ebola hemorrhagic fever, rabies, vesicular stomatitis, measles, peste desdriven ruminants, canine distemper,
- composition containing the substance having an inhibitory activity of HDAC in the present invention as an active ingredient can be used alone or as an adjuvant in treatment or prevention of the infections with pathogenic microorganisms to supplement the treatment and preventive action for the other infections known to those skilled in the art.
- composition containing the substance having an inhibitory activity of HDAC in the present invention as an active ingredient can be used as an anti-cancer agent and/ or as an adjuvant in treatment or prevention of cancers to supplement the other anticancer treatment.
- the most preferred embodiment in the prevention of the cancer is a prevention of cancer recurrence.
- cancers which are the subject of treatment or prevention in the present invention is not particularly limited, various cancers such as lung cancer, renal cell cancer, hepatocellular cancer, colon cancer and bladder cancer can be listed, preferably prostate cancer or oral cancer, more preferably breast cancer.
- the enhancer of cellular immunity of the present invention can be preferably applied in individual cases as far as B2M expression is suppressed, not necessarily in the diseases in which B2M supression is observed frequently (for example, breast cancer and prostate cancer).
- methods of the anti-cancer treatment are not particularly limited, but they includes various treatments such as radiotherapy, thermotherapy, chemotherapy (for example, anti-cancer agents such as anastrozole, cyclophosphamide, irinotecan, cytarabine, paclitaxel, docetaxel, busulfan, carboquone, mitobronitol, dacarbazine, melphalan, procarbazine, doxifluridine, fluorouracil, camofur, mercaptopurine, methotrexate, cytarabine ocfosphate, tegafur, carboplatin, cisplatin, thiotepa, doxorubicin, epirubicin, aclarubicin, L-asparaginase, mitomycin C, medroxyprogesterone, Krestin, tamoxifen, toremifene, vinorelbine and e
- Cancer vaccine therapy using tumor antigen peptide DNA vaccines that introduce peptide antigen or tumor-cell gene through vectors/carriers such as viruses into living bodies, RNA vaccines utilizing RNA in tumor cells, the treatments using cytokine and dendritic cells as antigen-presenting cells in combination, monoclonal antibody therapy, and the like are included in the immunotherapy.
- composition containing the substance having an inhibitory activity of HDAC in the present invention as an active component can be also used for producing the pharmaceuticals for the use to enhance cellular immunity.
- enhancers of cellular immunity are used for prevention, recurrence prevention and the like, besides treatment as well as the improvement of disease status, relating to various diseases according to the present invention.
- a method of administering a composition containing the substance having an inhibitory activity of HDAC in the present invention as an active component is not particularly limited, but, it is possible to administrate to a subject orally or parenterally (for example, intravenously including intravenous infusion, arterially, subcutaneously, intramuscularly, intraperitoneally, topically or the like).
- the subject for administration may be any animals, for example, lizard, chicken, domestic duck, wild duck, mouse, rat, canine, feline, sheep, goat, bovine, equine, porcine, monkey, human and others can be considered for them, and preferably mammals including human.
- a composition containing the substance having an inhibitory activity of HDAC in the present invention as an active component can be prepared by formulating together with pharmaceutical carriers which are used usually.
- HDAC inhibitor which is an active component can be prepared for oral administration as liquid oral formulation such as syrup, or processed into extract, powder and the like and blended with pharmaceutically acceptable carriers to prepare oral formulation such as tablet, capsule, syrup, emulsion, granule and powder.
- composition additives such as preservative, antioxidant, colorant and sweetener as needed.
- a composition containing the substance having an inhibitory activity of HDAC as an active component in the present invention can be used alone, but since it is used for the purpose of the enhancement of cellular immunity, it can be preferably used in combination with antigen-specific vaccines such as cancer antigen-specific vaccines and viral vaccines, as well as other antigen-nonspecificimmunostimulants, for example, cytokines such as interferone and various adjuvants.
- antigen-specific vaccines such as cancer antigen-specific vaccines and viral vaccines, as well as other antigen-nonspecificimmunostimulants, for example, cytokines such as interferone and various adjuvants.
- the pharmaceutical agents which are used in combination can be used either by mixing or separately with the pharmaceutical agents containing an HDAC inhibitor in the present invention.
- the second embodiment of the present invention relates to a method for enhancing cellular immunity including a step of administrating a composition containing the substance having an inhibitory activity of HDAC as an active component to a subject. That is, it is a method for enhancing cellular immunity in a subject suffering from, or at a risk of, a disease derived from decreased immunity, wherein the method includs a step of administrating a composition containing pharmaceutically acceptable carriers and the substance having an inhibitory activity of HDAC to the subject in a dosage of enhancing cellular immunity.
- a method for screening a subject having the disease in which B2M expression is suppressed at the diseased site, adequate for the method for enhancing cellular immunity in the present invention, or accordingly, a subject having or at a risk of occurrence/reoccurrence of the disease in which B2M expression is suppressed at the disease site, adequate for the method for enhancing cellular immunity according the present invention is also within the scope of the present invention, and the third embodiment of the present invention.
- the followings are included in such a screening:
- tissue can be obtained through lavage fluid, abrasion collection, body fluids such as blood, spinal fluid, lymph, urine, saliva, ascitic fluid, pleural fluid and exudate, or the like besides through biopsy which is usually used for each organ.
- body fluids such as blood, spinal fluid, lymph, urine, saliva, ascitic fluid, pleural fluid and exudate, or the like besides through biopsy which is usually used for each organ.
- comparison of the amounts of B2M or mRNA encoding B2M can be achieved by using a method known to those skilled in the art, for example by using mass spectrometer or an immunological method such as ELISA, radioimmunoassay, fluorescent antibody method, western blotting, immunohistochemical staining or the like; a genetic method such as northern blotting, RT-PCR, microarray or the like; or others.
- an immunological method such as ELISA, radioimmunoassay, fluorescent antibody method, western blotting, immunohistochemical staining or the like
- a genetic method such as northern blotting, RT-PCR, microarray or the like; or others.
- the screening is adequate for primary screening through which a subject to be applied the method of the present invention is selected, however, more stringently, it is preferred to further perform the screening including the following steps or to further narrow the subject to be selected by performing them from the first.
- chromatin immunoprecipitation is a method of affinity-precipitation of the DNA associating with chromatin together with the chromatin
- any appropriate methods can be used, however, for example, it is possible to maintain the associating status between chromatin and the DNA by pre- treating tissue cells with a cross-linker such as 1% formaldehyde (for example for 10 minutes at room temperature) followed by precipitating chromatin and the associated DNA fragment after lysing the cells using RIPA buffer which are used usually, and the like, and shearing the DNA using an ultrasonic wave homogenizer and the like (see Assam El-Osta et al., (2002) MOLECULAR AND CELLULAR BIOLOGY 22(6) pl844-1857).
- a cross-linker such as 1% formaldehyde
- the method for enhancing cellular immunity which is the second embodiment of the present invention is a method for enhancing HLA class I expression in a subject including a step of administrating the composition containing the substance having an inhibitory activity of HDAC as an active component to the subject.
- Such composition is used for treatment or as a preventive agent of the infection by pathogenic microorganism such as virus or used as an anti-cancer agent in treatment of the disease in which B2M is suppressed, for example, in treatment of cancer or used for the assistance of other treatment methods of the disease, but not limited to.
- a method for enhancing cellular immunity is a method for enhancing B2M expression in a subject including a step of administrating a composition containing the substance having an inhibitory activity of HDAC as an active component to the subject.
- Such composition is used for treating or preventing cancer, for example, alone or in combination with other treatment methods, but not limited to.
- the present example shows that the histone proteins binding to the intracellular B2M gene region are deacetylated and this deacetylation is cancelled by HDAC inhibitor.
- the following shows the procedure.
- Human breast cancer cell lines that is, MCF-7 cells and HMC-I cells were used to culture in the presence of 100 nM TSA (Sigma, USA) for 24 hours or 4mM VPA (Sigma, USA) for 48 hours, respectively followed by extracting chromatin from the cells according to the manufacturer's instructions (Upstate Inc., USA) and immuno- precipitating the chromatin using anti-acetylated histone H3 antibody (Upstate Inc., USAXsee Assam El-Osta, et al. 2002. MOLECULAR AND CELLULAR BIOLOGY 22(6). p.1844-1857).
- the genes binding to the acetylated histones were amplified by using PCR with the B2M gene-specific primers (GAAAACGGGAAAGTCCCTCT and AGATCCAGCCCTGGACTAGC), electrophoresed on 1% agarose gel followed by detecting with a transilluminator in the presence of ethidium bromide.
- the results showed that the histones of B2M gene region in any cancer cells were deacetylated.
- HDAC inhibitors such as TSA and VPA
- the present example shows that the expression of intracellular B2M protein is increased by HDAC inhibitor.
- the following shows the procedure.
- MCF-7 cells and HMC-I cells were cultured in the presence of TSA, a HDAC inhibitor, (100 nM) for 24 hours respectively, followed by harvesting them.
- 1X106 cells are lysed in 100 ml cell lysate (RIPA buffer) and a soluble fraction is harvested as a lysate. SDS sample buffer was added to the lysate.
- the transferred membrane was immersed in a primary antibody (anti-pan-HLA class I heavy chain antibody EMR8-5 (Hokudo, Sapporo), or anti-B2M antibody EMRB6 (Hokudo, Sapporo), or anti-actin antibody (DAKO), and incubated for one hour at room temperature.
- a primary antibody anti-pan-HLA class I heavy chain antibody EMR8-5 (Hokudo, Sapporo), or anti-B2M antibody EMRB6 (Hokudo, Sapporo), or anti-actin antibody (DAKO)
- the transferred membrane was immersed in a secondary antibody peroxidase- labeled anti-mouse IgG antibody (KPL, USA) and incubated for one hour at room temperature.
- KPL secondary antibody peroxidase- labeled anti-mouse IgG antibody
- Luminescent signals were detected by exposure to X ray film.
- MCF-7 cells and HMC-I cells were cultured for 24 hours in the presence of HDAC inhibitor TSA (100 nM) or for 48hours in the presence of HDAC inhibitor VPA (4 mM), respectively, and the level of MHC class I antigen expressing on the cell surface was analyzed by a flow cytometer (Becton Dickinson). The following shows the procedure.
- 1X106 cells were floated in 100 ml PBS buffer, added a primary antibody (an anti- pan-HLA class I antibody W6/32 (Barnstable, C. J., Bodmer, W. J., Brown, G., Galfre, G., Milstein, C, Williams, A. F., and Zeigler, A. (1978) Cell 14, 9-20)) and incubated for 40 minutes at 4oC.
- a primary antibody an anti- pan-HLA class I antibody W6/32 (Barnstable, C. J., Bodmer, W. J., Brown, G., Galfre, G., Milstein, C, Williams, A. F., and Zeigler, A. (1978) Cell 14, 9-20)
- the cells were washed twice with PBS, floated in PBS added with 1% formalin followed by analyzing FITC level of the cell surface by a flow cytometer.
- Hematoxylin nuclear stain was executed (one to two minutes). Hematoxylin nuclear stain was followed by the following procedure. 1. Take sections to water. 2. Place sections in Mayers Haematoxylin (filtrated) for 5 minutes.
- a human breast cancer cell line MCF7 cells were transplanted into SCID mice. After two weeks, subcutaneous tumor of about 5 mm in diameter was obtained. One mouse was supplied with water containing 0.4 % valproic acid (VPA, Sigma) for 10 days, and the other mouse was supplied with water with no additive as control. After ten days, the tumor was excised surgically, and 10 % formalin (as the mass was small, the concentration was set lower than in example 4 to prevent overfixation) was used to fix overnight at room temperature, and paraffin-embedded slices were obtained.
- VPN 0.4 % valproic acid
- HIV infection T cells (clone 8E5, purchased from ATCC) were cultured in 4 mM valproic acid-added culture medium (RPMI1640) or non additive culture medium for 48 hours, and reacted with an anti-pan-HLA class I antibody, W6/32 antibody and with FITC-labeled anti-mouse IgG antibody for 40 minutes respectively, and the cells were fixed in 0.1 % formalin/PBS.
- the fluorescence intensities were measured by flow cytometer (FACScan, Beckton Dickinson). The recovery of expression was observed in the infected cell group in which the HLA class I level on a cell surface was decreased, in the presence of the HDAC inhibitor.
- Papilloma virus persistent infection cells were cultured in 4 mM valproic acid-added culture medium (RPMI 1640) or non additive culture medium for 48 hours, and reacted with an anti-pan-HLA class I antibody, W6/32 antibody and with FITC-labeled anti-mouse IgG antibody for 40 minutes respectively, and the cells were fixed in 0.1 % formalin/PBS.
- the fluorescence intensities were measured by flow cytometer (FACScan, Beckton Dickinson). The recovery of expression was observed in the infected cell group in which the HLA class I level on a cell surface was decreased, in the presence of the HDAC inhibitor.
- EB virus persistent infection B cells (LG2EBV cells) were cultured in 4 mM valproic acid-added culture medium (RPMIl 640) or non additive culture medium for 48 hours, and reacted with an anti-pan-HLA class I antibody, W6/32 antibody and with FITC- labeled anti-mouse IgG antibody for 40 minutes respectively, and the cells were fixed in 0.1 % formalin/PBS.
- the fluorescence intensities were measured by flow cytometer (FACScan, Beckton Dickinson). The recovery of expression was observed in the infective cell group in which the HLA class I level on a cell surface was decreased, in the presence of the HDAC inhibitor.
- Mumps virus persistent infection B cells (Akata-MPl cells) were cultured in 4 mM valproic acid-added culture medium (RPMI 1640) or non additive culture medium for 48 hours, and reacted with an anti-pan-HLA class I antibody, W6/32 antibody and with FITC-labeled anti-mouse IgG antibody for 40 minutes respectively, and the cells were fixed in 0.1 % formalin/PBS.
- the fluorescence intensities were measured by flow cytometer (FACScan, Beckton Dickinson). The recovery of expression was observed in the infective cell group in which the HLA class I level on a cell surface was decreased, in the presence of the HDAC inhibitor.
- Measles virus persistent infection B cells (Raji-ZH cells) were cultured in 4 mM valproic acid-added culture medium (RPMI 1640) or non additive culture medium for 48 hours, and reacted with an anti-pan-HLA class I antibody, W6/32 antibody and with FITC-labeled anti-mouse IgG antibody for 40 minutes respectively, and the cells were fixed in 0.1 % formalin/PBS.
- the fluorescence intensities were measured by flow cytometer (FACScan, Beckton Dickinson). The recovery of expression was observed in the infective cell group in which the HLA class I level on a cell surface was decreased, in the presence of the HDAC inhibitor.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/448,073 US20100093862A1 (en) | 2006-12-06 | 2007-12-06 | Potentiation of cellular immunity using histone deacetylase (hdac) inhibitors. |
CA002671649A CA2671649A1 (en) | 2006-12-06 | 2007-12-06 | Potentiation of cellular immunity using histone deacetylase (hdac) inhibitors |
JP2009524035A JP4887427B2 (en) | 2006-12-06 | 2007-12-06 | Cellular immunity enhancer using substance having histone deacetylase inhibitory activity |
EP07850583A EP2091525A1 (en) | 2006-12-06 | 2007-12-06 | Potentiation of cellular immunity using histone deacetylase (hdac) inhibitors |
AU2007328872A AU2007328872A1 (en) | 2006-12-06 | 2007-12-06 | Potentiation of cellular immunity using histone deacetylase (HDAC) inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87322306P | 2006-12-06 | 2006-12-06 | |
US60/873,223 | 2006-12-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008069349A1 true WO2008069349A1 (en) | 2008-06-12 |
Family
ID=39124589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/074067 WO2008069349A1 (en) | 2006-12-06 | 2007-12-06 | Potentiation of cellular immunity using histone deacetylase (hdac) inhibitors |
Country Status (7)
Country | Link |
---|---|
US (1) | US20100093862A1 (en) |
EP (1) | EP2091525A1 (en) |
JP (1) | JP4887427B2 (en) |
CN (1) | CN101626763A (en) |
AU (1) | AU2007328872A1 (en) |
CA (1) | CA2671649A1 (en) |
WO (1) | WO2008069349A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013182660A1 (en) * | 2012-06-06 | 2013-12-12 | Bionor Immuno As | Hiv vaccine |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140206678A1 (en) * | 2011-01-27 | 2014-07-24 | Kadmon Corporation, Llc | Inhibitors of mtor kinase as anti -viral agent |
US9821054B2 (en) * | 2011-03-11 | 2017-11-21 | Turnstone Limited Partnership | Method of vaccination comprising a histone deacetylase inhibitor |
CN104982082B (en) | 2012-11-30 | 2019-01-08 | 国家科学和工业研究组织 | wireless backhaul system |
RU2015139054A (en) | 2013-03-14 | 2017-04-19 | Дженентек, Инк. | METHODS FOR TREATING CANCER AND PREVENTION OF DRUG RESISTANCE OF CANCER |
CN105617381B (en) * | 2014-10-30 | 2019-07-05 | 中国科学院上海巴斯德研究所 | The new application of histon deacetylase (HDAC) inhibitor treatment β subfamily herpesviral |
BR112018074192A8 (en) | 2016-05-25 | 2022-11-08 | Inst Nat Sante Rech Med | METHOD FOR TREATMENT OF A SUBJECT, METHOD FOR PRODUCING A CELL COMPOSITION, CELL COMPOSITION, VACCINE COMPOSITION AND KIT |
AU2018269937A1 (en) * | 2017-05-19 | 2020-01-02 | Memorial Sloan Kettering Cancer Center | Methods for modifying endoplasmic reticulum processing of protein |
CN111671742B (en) * | 2020-05-17 | 2023-08-25 | 中国人民解放军军事科学院军事医学研究院 | Application of sodium valproate in preparation of medicine for treating pneumonia caused by human coronavirus infection |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002007722A2 (en) * | 2000-07-07 | 2002-01-31 | Georg-Speyer-Haus | Valproic acid and derivatives thereof as histone deacetylase inhibitors |
EP1529527A2 (en) * | 2001-09-18 | 2005-05-11 | G2M Cancer Drugs AG | Valproic acid for a combination treatment of human cancers, tumor metastasis and minimal residual disease |
WO2005105055A1 (en) * | 2004-04-30 | 2005-11-10 | Topotarget Germany Ag | Formulation comprising histone deacetylase inhibitors |
WO2007131364A1 (en) * | 2006-05-16 | 2007-11-22 | Mcgill University | Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1010705A4 (en) * | 1997-09-02 | 2004-09-15 | Sumitomo Pharma | Novel cyclic tetrapeptide derivatives and medicinal use thereof |
US6518012B1 (en) * | 1999-04-02 | 2003-02-11 | Health Research, Inc. | Method for regulating the expression of MHC antigens and CD40 by inhibitors of histone deacetylation |
-
2007
- 2007-12-06 CA CA002671649A patent/CA2671649A1/en not_active Abandoned
- 2007-12-06 JP JP2009524035A patent/JP4887427B2/en not_active Expired - Fee Related
- 2007-12-06 WO PCT/JP2007/074067 patent/WO2008069349A1/en active Application Filing
- 2007-12-06 CN CN200780044958A patent/CN101626763A/en active Pending
- 2007-12-06 EP EP07850583A patent/EP2091525A1/en not_active Withdrawn
- 2007-12-06 US US12/448,073 patent/US20100093862A1/en not_active Abandoned
- 2007-12-06 AU AU2007328872A patent/AU2007328872A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002007722A2 (en) * | 2000-07-07 | 2002-01-31 | Georg-Speyer-Haus | Valproic acid and derivatives thereof as histone deacetylase inhibitors |
EP1529527A2 (en) * | 2001-09-18 | 2005-05-11 | G2M Cancer Drugs AG | Valproic acid for a combination treatment of human cancers, tumor metastasis and minimal residual disease |
WO2005105055A1 (en) * | 2004-04-30 | 2005-11-10 | Topotarget Germany Ag | Formulation comprising histone deacetylase inhibitors |
WO2007131364A1 (en) * | 2006-05-16 | 2007-11-22 | Mcgill University | Hybrid molecules having mixed vitamin d receptor agonism and histone deacetylase inhibitory properties |
Non-Patent Citations (6)
Title |
---|
"AIDS heilen - mit Valproinsäure?", DEUTSCHE APOTHEKER ZEITUNG, vol. 146, no. 6, 9 February 2006 (2006-02-09), pages 39 - 41, XP002471610, Retrieved from the Internet <URL:http://www.deutscher-apotheker-verlag.de/daz_neu/intern/daz/06/06/36453.html> [retrieved on 20080304] * |
ACHACHI A ET AL: "Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo", PNAS, vol. 102, no. 29, 19 July 2005 (2005-07-19), pages 10309 - 10314, XP002471611 * |
ARMEANU S ET AL: "Natural killer cell-mediated lysis of heptoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate", CANCER RESEARCH, vol. 65, no. 14, 15 July 2005 (2005-07-15), pages 6321 - 6329, XP002471613 * |
LEHRMAN ET AL: "Depletion of latent HIV-1 infection in vivo: a proof-of-concept study", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 366, no. 9485, 13 August 2005 (2005-08-13), pages 549 - 555, XP005025452, ISSN: 0140-6736 * |
TAKAI N ET AL: "Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells", CLINICAL CANCER RESEARCH, vol. 10, 2004, pages 1141 - 1149, XP002471612 * |
TORU WATANABE ET AL: "Secondary renal Fanconi syndrome caused by valproate therapy", PEDIATRIC NEPHROLOGY ; JOURNAL OF THE INTERNATIONAL PEDIATRIC NEPHROLOGY ASSOCIATION, SPRINGER-VERLAG, BE, vol. 20, no. 6, 1 June 2005 (2005-06-01), pages 814 - 817, XP019347851, ISSN: 1432-198X * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013182660A1 (en) * | 2012-06-06 | 2013-12-12 | Bionor Immuno As | Hiv vaccine |
US10335482B2 (en) | 2012-06-06 | 2019-07-02 | Bionor Immuno As | Method of inducing an anti-HIV-1 immune response comprising administering a C5/TM-GP41 peptide dimer |
Also Published As
Publication number | Publication date |
---|---|
JP2010511597A (en) | 2010-04-15 |
JP4887427B2 (en) | 2012-02-29 |
EP2091525A1 (en) | 2009-08-26 |
US20100093862A1 (en) | 2010-04-15 |
CN101626763A (en) | 2010-01-13 |
CA2671649A1 (en) | 2008-06-12 |
AU2007328872A1 (en) | 2008-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100093862A1 (en) | Potentiation of cellular immunity using histone deacetylase (hdac) inhibitors. | |
Bourgeois-Daigneault et al. | Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy | |
Gama et al. | Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques | |
Amatore et al. | Influenza virus replication in lung epithelial cells depends on redox‐sensitive pathways activated by NOX4‐derived ROS | |
CN102026645B (en) | Oncolytic rhabdovirus | |
BR112019023323A2 (en) | compositions to facilitate membrane fusion and uses thereof | |
Choi et al. | Effects of NOX1 on fibroblastic changes of endothelial cells in radiation‑induced pulmonary fibrosis | |
JP2010516628A (en) | HAT acetylated promoter and use of the composition in promoting immunogenicity | |
Roos et al. | Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus | |
Yan et al. | Heat shock cognate protein 70 gene is required for prevention of apoptosis induced by WSSV infection | |
Li et al. | Clearance of HIV infection by selective elimination of host cells capable of producing HIV | |
Ellerhoff et al. | Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus | |
Tafaleng et al. | Hepatocyte nuclear factor 4 alpha 2 messenger RNA reprograms liver‐enriched transcription factors and functional proteins in end‐stage cirrhotic human hepatocytes | |
Kamperschroer et al. | The role of proinflammatory cytokines in wasting disease during lymphocytic choriomeningitis virus infection | |
Fumagalli et al. | Antibody-independent protection against heterologous SARS-CoV-2 challenge conferred by prior infection or vaccination | |
Ji et al. | GAS6 attenuates sepsis-induced cardiac dysfunction through NLRP3 inflammasome-dependent mechanism | |
Burnet et al. | Hemin treatment drives viral reactivation and plasma cell differentiation of EBV latently infected B cells | |
Pino et al. | Limited impact of fingolimod treatment during the initial weeks of ART in SIV-infected rhesus macaques | |
US10335481B2 (en) | Gene-modified measles virus for tumor treatment use | |
CZ2017839A3 (en) | The use of hem arginate for the production of a medicament for reducing the size of the HIV-1 latent reservoir in vivo | |
Ye et al. | RKIP suppresses the influenza A virus-induced airway inflammatory response via the ERK/MAPK pathway | |
Zeng et al. | ORMDL3 restrains type-I interferon signaling and anti-tumor immunity by promoting RIG-I degradation | |
Zadaloo et al. | Inhibition of Autophagy by 3-MA Increases Oncolysis Effect of VSV in a Murine Model of Cancer | |
Sun | Investigating the role of the bone marrow microenvironment in multiple myeloma | |
EP3366296B1 (en) | Methods for using regulators for increasing the expression or activation of p53 and/or regulators for reducing or inhibiting the expression of p63-alpha, for the treatment of non-alcoholic fatty liver disease (nafld) and/or non-alcoholic steatohepatitis (nash) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780044958.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07850583 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007328872 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2671649 Country of ref document: CA Ref document number: 2007850583 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2009524035 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12448073 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007328872 Country of ref document: AU Date of ref document: 20071206 Kind code of ref document: A |